Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
385.00    0.00 (0.00%)
Bid:
375.00
Ask:
395.00
Spread: 20.00 (5.333%)
Market Cap: £185.99m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

Study shows Tristel Wipes System benefits

12 Oct 2016 08:12

RNS Number : 3198M
Tristel PLC
12 October 2016
 

 

 

Tristel plc

("Tristel" or "the Company")

 

Comparison of high-level disinfectants for flexible nasendoscopes published in

The Journal of Laryngology & Otology

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces that in a randomised, single-blind comparison of disinfectants used in Ear, Nose and Throat clinics, its Wipes System proved to be the equal in terms of microbiological efficacy to disinfectants produced by Du Pont and Johnson & Johnson. In the study Du Pont's PeraSafe peracetic acid disinfectant was used in a tray, and Johnson & Johnson's Cidex OPA ortho phthalaldehyde disinfectant was used in an automated washer-disinfector manufactured by Medvators Inc. The Tristel Wipes System is a stand-alone process requiring no equipment, support building services, or maintenance. The study concluded that the Wipes System has no capital outlay cost, the lowest running cost, the greatest convenience, and the fastest turnaround time for medical instruments of the three products evaluated.

 

The study, which was conducted by the Bay of Plenty District Health Board, Tauranga, New Zealand in 2011 has been published in the The Journal of Laryngology & Otology [Hitchcock, B., Moynan, S., Frampton, C., Reuther, R., Gilling, P. and Rowe, F. (2016) 'A randomised, single-blind comparison of high-level disinfectants for flexible nasendoscopes', The Journal of Laryngology Otology, pp. 1-7. doi: 10.1017/S0022215116008860]. Preliminary results of the study were presented at the 11th Congress for German Hospital Hygiene held in Berlin in March 2012, and reported by an RNS Reach on 29 March 2012.

 

The Tristel Wipes System is a unique, patented decontamination method for non-lumened scopes and probes. It has been a very significant sales success for the Company globally. Worldwide sales in the financial year ending June 2012 were £3.3m and are expected to be £8.7m in the year ending June 2016.

 

Paul Swinney, CEO, comments: "We are pleased to see at long last the publication in a peer-reviewed journal of this significant study comparing our Wipes System with competitor products manufactured by two of the world's major infection prevention companies. The results affirm the key advantages of our Wipes over alternative chemistries and disinfection methods. This is the twenty-fifth peer-reviewed and published scientific paper featuring Tristel products - a body of evidence of our products' attributes that forms one of our Company's key strengths."

 

For further information please contact:

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

 

Liz Dixon, Finance Director

 

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

finnCap

Tel: 020 7600 1658

Geoff Nash/ Giles Rolls (Corporate Finance)

 

Stephen Norcross (Corporate Broking)

 

   

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAAKBDKOBDKPKD
Date   Source Headline
7th Jul 20263:04 pmRNSHolding(s) in Company
7th Jul 20267:00 amRNS-RAPIC26 Annual Conference attendance
17th Jun 20267:00 amRNSAppointment of CEO
16th Jun 202612:00 pmRNSHolding(s) in Company
10th Jun 20267:00 amRNSExercise of Share Options & Total Voting Rights
13th May 202610:10 amRNSExercise of Share Options and Total Voting Rights
5th May 20267:00 amRNSExercise of Share Options and Total Voting Rights
20th Apr 20262:28 pmRNSHolding(s) in Company
20th Apr 20268:20 amRNSHolding(s) in Company
23rd Mar 20267:00 amRNSDirector/PDMR Shareholding
18th Mar 20267:00 amRNS-RConference attendance at ShareSoc Leeds
17th Mar 20265:13 pmRNSHolding(s) in Company
3rd Mar 20264:04 pmRNSPCA Dealing
2nd Mar 20267:00 amRNSHalf-year Financial Report
12th Feb 20267:00 amRNSExercise of Share Options and Total Voting Rights
6th Feb 202611:56 amRNSExercise of Share Options and Total Voting Rights
6th Feb 20267:00 amRNSNotice of Results
22nd Jan 20267:00 amRNSPositive H1 Trading Update & Directorate Change
8th Jan 20263:10 pmRNSExercise of Share Options and Total Voting Rights
12th Dec 202510:37 amRNSDirector/PDMR Shareholding
12th Dec 20259:19 amRNSExercise of Share Options and Total Voting Rights
11th Dec 202511:54 amRNSResult of AGM
11th Dec 20257:00 amRNSAGM Statement
24th Nov 202512:28 pmRNSDirector Option Grant
24th Nov 20257:00 amRNSUpdated US guidelines for high level disinfection
18th Nov 20257:00 amRNSNotice of AGM & Posting of Annual Report &Accounts
12th Nov 202511:33 amRNSHolding(s) in Company
31st Oct 20254:11 pmRNSHolding(s) in Company
31st Oct 20252:12 pmRNSHolding(s) in Company
22nd Oct 20254:56 pmRNSHolding(s) in Company
16th Oct 20254:00 pmRNSExercise of Share Options and Total Voting Rights
13th Oct 202512:00 pmRNSExercise of Share Options and Total Voting Rights
13th Oct 20257:00 amRNSFinal Results
9th Oct 202510:06 amRNSExercise of Share Options and Total Voting Rights
25th Sep 20257:00 amRNSVISICLEAN Product Launch
16th Sep 20257:00 amRNSNotice of Preliminary Results
11th Sep 20257:00 amRNSExercise of Share Options and Total Voting Rights
1st Sep 20257:00 amRNSConfirmation of CFO Appointment
21st Aug 20253:56 pmRNSHolding(s) in Company
18th Aug 202512:15 pmRNSExercise of Share Options and Total Voting Rights
6th Aug 20254:05 pmRNS-RCapital Markets Day video update
29th Jul 20257:00 amRNSTrading update
24th Jul 20257:00 amRNSConfirmation of Investor presentations
17th Jul 20257:00 amRNSAppointment of Chief Financial Officer
4th Jul 20251:02 pmRNSHolding(s) in Company
26th Jun 20257:00 amRNS-RAPIC25 Annual Conference attendance
2nd Jun 20257:00 amRNSInvestor Presentations & Notice of Trading Update
30th May 20257:00 amRNSHolding(s) in Company
28th May 20257:00 amRNS-RConference attendance at Mello2025 Investor event
16th May 20257:00 amRNSExercise of Share Options and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.